The role of iron in brain ageing and neurodegenerative disorders

The Lancet Neurology

Volumn 13, Issue 10, 2014, Pages 1045-1060

  Ward, Roberta J ^a,b   Zucca, Fabio A ^c   Duyn, Jeff H ^d   Crichton, Robert R ^b   Zecca, Luigi ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,7 DICHLORO 2 [(DIMETHYLAMINO)METHYL] 8 HYDROXYQUINOLINE; CARBOHYDRATE; CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DNA; FERRITIN; FERROPORTIN; FERROUS ION; HEPCIDIN; HEPHAESTIN; IRON; IRON CHELATING AGENT; IRON REGULATORY FACTOR; LIPID; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NEUROMELANIN; PROTEIN; QUINOLINE DERIVATIVE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; NONHEME IRON PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; CELL DAMAGE; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON CHELATION; IRON METABOLISM; IRON TRANSPORT; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; OXYGEN TRANSPORT; PARKINSON DISEASE; PATHOPHYSIOLOGY; REGULATORY MECHANISM; RESTLESS LEGS SYNDROME; REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; BRAIN; BRAIN LEVEL; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PROCEDURES;

AGING; ANIMALS; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; HUMANS; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NONHEME IRON PROTEINS;

EID: 84907999177     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70117-6     Document Type: Review

References (224)

1. Crichton RR Inorganic biochemistry of iron metabolism from molecular mechanisms to clinical consequences 2009, 461. John Wiley & Sons, Chichester.
2. Hentze MW, Muckenthaler MU, Galy B, Camaschella C Two to tango: regulation of Mammalian iron metabolism. Cell 2010, 142:24-38.
3. Wang J, Pantopoulos K Regulation of cellular iron metabolism. Biochem J 2011, 434:365-381.
4. Kruszewski M Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003, 531:81-92.
5. Zecca L, Gallorini M, Schünemann V, et al. Iron, Neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001, 76:1766-1773.
6. Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004, 101:9843-9848.
7. Andrews NC, Schmidt PJ Iron homeostasis. Annu Rev Physiol 2007, 69:69-85.
8. Mills E, Dong XP, Wang F, Xu H Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem 2010, 2:51-64.
9. Andrews NC Forging a field: the golden age of iron biology. Blood 2008, 112:219-230.
10. Garrick MD, Garrick LM Cellular iron transport. Biochim Biophys Acta 2009, 1790:309-325.
11. Muckenthaler MU, Galy B, Hentze MW Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008, 28:197-213.
12. Wallander ML, Leibold EA, Eisenstein RS Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim Biophys Acta 2006, 1763:668-689.
13. Moos T, Morgan EH Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 2000, 20:77-95.
14. Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH Iron trafficking inside the brain. J Neurochem 2007, 103:1730-1740.
15. Ke Y, Qian ZM Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol 2007, 83:149-173.
16. Leitner DF, Connor JR Functional roles of transferrin in the brain. Biochim Biophys Acta 2012, 1820:393-402.
17. Jeong SY, David S Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003, 278:27144-27148.
18. Dringen R, Bishop GM, Koeppe M, Dang TN, Robinson SR The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res 2007, 32:1884-1890.
19. Huang E, Ong WY, Go ML, Connor JR Upregulation of iron regulatory proteins and divalent metal transporter-1 isoforms in the rat hippocampus after kainate induced neuronal injury. Exp Brain Res 2006, 170:376-386.
20. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312:162-163.
21. Zucca FA, Cupaioli FA, Zecca L The role of iron in neurodegeneration. Neurodegeneration: metallostasis and proteostasis 2011, 174-211. RSC Publishing. D. Milardi, E. Rizzarelli (Eds.).
22. Boserup MW, Lichota J, Haile D, Moos T Heterogenous distribution of ferroportin-containing neurons in mouse brain. Biometals 2011, 24:357-375.
23. Moos T, Bernth N, Courtois Y, Morgan EH Developmental iron uptake and axonal transport in the retina of the rat. Mol Cell Neurosci 2011, 46:607-613.
24. Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, Ghosh MC, McConnell JP, Rouault TA Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 2005, 106:1084-1091.
25. Abbott NJ, Rönnbäck L, Hansson E Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
26. Xu J, Ling EA Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J Anat 1994, 184:227-237.
27. Wu LJ, Leenders AG, Cooperman S, et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res 2004, 1001:108-117.
28. Connor JR, Menzies SL, St Martin SM, Mufson EJ Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 1990, 27:595-611.
29. Badaracco ME, Siri MV, Pasquini JM Oligodendrogenesis: the role of iron. Biofactors 2010, 36:98-102.
30. Connor JR, Menzies SL Relationship of iron to oligodendrocytes and myelination. Glia 1996, 17:83-93.
31. Crichton RR, Ward RJ Metal based neurodegeneration: from molecular mechanisms to therapeutic strategies 2006, J Wiley and Son, Chichester.
32. Rathore KI, Redensek A, David S Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1. Glia 2012, 60:738-750.
33. Connor JR, Menzies SL Cellular management of iron in the brain. J Neurol Sci 1995, 134(suppl):33-44.
34. Lee P, Peng H, Gelbart T, Beutler E The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA 2004, 101:9263-9265.
35. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
36. Urrutia P, Aguirre P, Esparza A, et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J Neurochem 2013, 126:541-549.
37. Conde JR, Streit WJ Microglia in the aging brain. J Neuropathol Exp Neurol 2006, 65:199-203.
38. Farrall AJ, Wardlaw JM Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging 2009, 30:337-352.
39. Killilea DW, Wong SL, Cahaya HS, Atamna H, Ames BN Iron accumulation during cellular senescence. Ann N Y Acad Sci 2004, 1019:365-367.
40. Williams R, Buchheit CL, Berman NE, LeVine SM Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012, 120:7-25.
41. Xu J, Jia Z, Knutson MD, Leeuwenburgh C Impaired iron status in aging research. Int J Mol Sci 2012, 13:2368-2386.
42. Hallgren B, Sourander P The effect of age on the non-haemin iron in the human brain. J Neurochem 1958, 3:41-51.
43. Ramos P, Santos A, Pinto NR, Mendes R, Magalhães T, Almeida A Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 2014, 28:13-17.
44. Hebbrecht G, Maenhaut W, De Reuck J Brain trace elements and aging. Nucl Instrum Methods Phys Res B 1999, 150:208-213.
45. Zecca L, Shima T, Stroppolo A, et al. Interaction of Neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996, 73:407-415.
46. Zecca L, Tampellini D, Rizzio E, Giaveri G, Gallorini M The determination of iron and other metals by INAA in cortex, cerebellum and putamen of human brain and in their neuromelanins. J Radioanal Nucl Chem 2001, 248:129-131.
47. House E, Esiri M, Forster G, Ince PG, Exley C Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. Metallomics 2012, 4:56-65.
48. Bartzokis G, Tishler TA, Lu PH, et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007, 28:414-423.
49. Aquino D, Bizzi A, Grisoli M, et al. Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 2009, 252:165-172.
50. Bartzokis G, Lu PH, Tingus K, et al. Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology 2011, 36:1375-1384.
51. Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012, 59:2625-2635.
52. Zucca FA, Bellei C, Giannelli S, et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm 2006, 113:757-767.
53. Zecca L, Bellei C, Costi P, et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc Natl Acad Sci USA 2008, 105:17567-17572.
54. Block ML, Zecca L, Hong JS Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
55. Lopes KO, Sparks DL, Streit WJ Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 2008, 56:1048-1060.
56. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 2009, 110:469-485.
57. Crichton RR, Ward RJ Metal based neurodegeneration: from molecular mechanisms to therapeutic strategies 2014, J Wiley & Sons, Chichester. 2nd edn.
58. Melis JP, van Steeg H, Luijten M Oxidative DNA damage and nucleotide excision repair. Antioxid Redox Signal 2013, 18:2409-2419.
59. Kwok JB Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2010, 2:671-682.
60. Catalá A Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids 2009, 157:1-11.
61. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A Protein carbonylation in human diseases. Trends Mol Med 2003, 9:169-176.
62. Perluigi M, Coccia R, Butterfield DA 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid Redox Signal 2012, 17:1590-1609.
63. Mastroberardino PG, Hoffman EK, Horowitz MP, et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis 2009, 34:417-431.
64. Horowitz MP, Greenamyre JT Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis 2010, 20(suppl 2):S551-S568.
65. Schipper HM, Kotake Y, Janzen EG Catechol oxidation by peroxidase-positive astrocytes in primary culture: an electron spin resonance study. J Neurosci 1991, 11:2170-2176.
66. Sulzer D, Zecca L Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 2000, 1:181-195.
67. Paris I, Martinez-Alvarado P, Cárdenas S, et al. Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 2005, 18:415-419.
68. Di Monte DA, Schipper HM, Hetts S, Langston JW Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia 1995, 15:203-206.
69. Hare DJ, Adlard PA, Doble PA, Finkelstein DI Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics 2013, 5:91-109.
70. Li WJ, Jiang H, Song N, Xie JX Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci Bull 2010, 26:205-210.
71. Yamamoto A, Shin RW, Hasegawa K, et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 2002, 82:1137-1147.
72. Liu Y, Connor JR Iron and ER stress in neurodegenerative disease. Biometals 2012, 25:837-845.
73. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
74. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012, 149:1060-1072.
75. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA The role of metallobiology and amyloid-β peptides in Alzheimer's disease. J Neurochem 2012, 120(suppl 1):149-166.
76. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000, 74:270-279.
77. Perry G, Nunomura A, Hirai K, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 2002, 33:1475-1479.
78. Altamura S, Muckenthaler MU Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 2009, 16:879-895.
79. Guillemot J, Canuel M, Essalmani R, Prat A, Seidah NG Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin. Hepatology 2013, 57:2514-2524.
80. Silvestri L, Camaschella C A potential pathogenetic role of iron in Alzheimer's disease. J Cell Mol Med 2008, 12:1548-1550.
81. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002, 277:45518-45528.
82. Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142:857-867.
83. Ebrahimi KH, Hagedoorn PL, Hagen WR A synthetic peptide with the putative iron binding motif of amyloid precursor protein (APP) does not catalytically oxidize iron. PLoS One 2012, 7:e40287.
84. Honarmand Ebrahimi K, Dienemann C, Hoefgen S, Than ME, Hagedoorn PL, Hagen WR The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain. PLoS One 2013, 8:e72177.
85. Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012, 18:291-295.
86. Schenck JF Magnetic resonance imaging of brain iron. J Neurol Sci 2003, 207:99-102.
87. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005, 23:1-25.
88. Jack CR, Wengenack TM, Reyes DA, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 2005, 25:10041-10048.
89. Nabuurs RJ, Hegeman I, Natté R, et al. High-field MRI of single histological slices using an inductively coupled, self-resonant microcoil: application to ex vivo samples of patients with Alzheimer's disease. NMR Biomed 2011, 24:351-357.
90. Antharam V, Collingwood JF, Bullivant JP, et al. High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron. Neuroimage 2012, 59:1249-1260.
91. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106:20954-20959. the Alzheimer's Disease Neuroimaging Initiative.
92. Schröder N, Figueiredo LS, de Lima MN Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies. J Alzheimers Dis 2013, 34:797-812.
93. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
94. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998, 70:2212-2215.
95. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 2005, 30:201-205.
96. Leskovjan AC, Kretlow A, Lanzirotti A, Barrea R, Vogt S, Miller LM Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. Neuroimage 2011, 55:32-38.
97. Hui Y, Wang D, Li W, et al. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J Alzheimers Dis 2011, 26:299-313.
98. Schipper HM, Cissé S, Stopa EG Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995, 37:758-768.
99. Schipper HM, Bennett DA, Liberman A, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 2006, 27:252-261.
100. Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 330:1219-1220.
101. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989, 52:1830-1836.
102. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989, 52:515-520.
103. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991, 56:446-451.
104. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133:3423-3433.
105. Gröger A, Berg D Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 2012, 119:1523-1528.
106. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
107. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57:176-179.
108. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995, 92:9603-9607.
109. Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008, 105:18578-18583.
110. Borie C, Gasparini F, Verpillat P, et al. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 2002, 249:801-804. the French Parkinson's disease genetic study group.
111. Guerreiro RJ, Bras JM, Santana I, et al. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 2006, 6:24.
112. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 1990, 2:327-340.
113. el-Agnaf OM, Irvine GB Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans 2002, 30:559-565.
114. Uversky VN, Li J, Fink AL Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276:44284-44296.
115. Castellani RJ, Siedlak SL, Perry G, Smith MA Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 2000, 100:111-114.
116. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990, 55:16-20.
117. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
118. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994, 36:876-881.
119. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995, 65:717-724.
120. Griffiths PD, Dobson BR, Jones GR, Clarke DT Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999, 122:667-673.
121. Faucheux BA, Martin ME, Beaumont C, et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 2002, 83:320-330.
122. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 1992, 59:1168-1171.
123. Good PF, Olanow CW, Perl DP Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992, 593:343-346.
124. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003, 86:1142-1148.
125. McGeer PL, Itagaki S, Boyes BE, McGeer EG Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
126. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
127. Zecca L, Wilms H, Geick S, et al. Human Neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 2008, 116:47-55.
128. Zhang W, Phillips K, Wielgus AR, et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011, 19:63-72.
129. Lewis MM, Du G, Kidacki M, et al. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging 2013, 34:1497-1503.
130. Yu X, Du T, Song N, et al. Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease. Neurology 2013, 80:492-495.
131. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, Rios C Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett 1999, 265:155-158.
132. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008, 33:1717-1723.
133. Martínez-Hernández R, Montes S, Higuera-Calleja J, et al. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochem Res 2011, 36:2111-2115.
134. Olivieri S, Conti A, Iannaccone S, et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 2011, 31:18568-18577.
135. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 2002, 22:6578-6586.
136. Ayton S, Lei P, Duce JA, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013, 73:554-559.
137. Hochstrasser H, Bauer P, Walter U, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63:1912-1917.
138. Pichler I, Del Greco M F, Gögele M, et al. Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. PLoS Med 2013, 10:e1001462. the PD GWAS Consortium, the International Parkinson's Disease Genomics Consortiumthe International Parkinson's Disease Genomics Consortium, the Wellcome Trust Case Control Consortium 2the Wellcome Trust Case Control Consortium 2, the Genetics of Iron Status Consortiumthe Genetics of Iron Status Consortium.
139. Miyake Y, Tanaka K, Fukushima W, et al. Dietary intake of metals and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci 2011, 306:98-102. the Fukuoka Kinki Parkinson's Disease Study Group.
140. Logroscino G, Chen H, Wing A, Ascherio A Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord 2006, 21:835-838.
141. Savica R, Grossardt BR, Carlin JM, et al. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology 2009, 73:1381-1387.
142. Levenson CW, Cutler RG, Ladenheim B, Cadet JL, Hare J, Mattson MP Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol 2004, 190:506-514.
143. Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov Disord 2011, 26:713-718.
144. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
145. Martin WR, Wieler M, Gee M Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
146. Savoiardo M Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003, 24(suppl 1):S35-S37.
147. Boelmans K, Holst B, Hackius M, et al. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2012, 27:421-427.
148. Nakane T, Nihashi T, Kawai H, Naganawa S Visualization of neuromelanin in the substantia nigra and locus ceruleus at 1·5T using a 3D-gradient echo sequence with magnetization transfer contrast. Magn Reson Med Sci 2008, 7:205-210.
149. Sasaki M, Shibata E, Kudo K, Tohyama K Neuromelanin-sensitive MRI. Basics, technique and clinical applications. Clin Neuroradiol 2008, 18:147-153.
150. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006, 17:1215-1218.
151. Ohtsuka C, Sasaki M, Konno K, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using Neuromelanin-sensitive MR imaging. Neurosci Lett 2013, 541:93-98.
152. Bouwmans AE, Vlaar AM, Srulijes K, Mess WH, Weber WE Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes. Int Rev Neurobiol 2010, 90:121-146.
153. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and Neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005, 20:1278-1285.
154. Song N, Wang J, Jiang H, Xie J Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med 2010, 48:332-341.
155. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994, 660:8-18.
156. Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009, 19:3-8.
157. Ropele S, de Graaf W, Khalil M, et al. MRI assessment of iron deposition in multiple sclerosis. J Magn Reson Imaging 2011, 34:13-21.
158. Lassmann H, van Horssen J, Mahad D Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012, 8:647-656.
159. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008, 64:707-713.
160. Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011, 134:3602-3615.
161. Yao B, Bagnato F, Matsuura E, et al. Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012, 262:206-215.
162. Mehindate K, Sahlas DJ, Frankel D, et al. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem 2001, 77:1386-1395.
163. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
164. Pandolfo M Friedreich ataxia: new pathways. J Child Neurol 2012, 27:1204-1211.
165. Ye H, Rouault TA Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry 2010, 49:4945-4956.
166. Waldvogel D, van Gelderen P, Hallett M Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999, 46:123-125.
167. Koeppen AH Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011, 303:1-12.
168. Keogh MJ, Chinnery PF Current concepts and controversies in neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 2012, 19:51-56.
169. Schipper HM Neurodegeneration with brain iron accumulation-clinical syndromes and neuroimaging. Biochim Biophys Acta 2012, 1822:350-360.
170. Rouault TA Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci 2013, 14:551-564.
171. Dusek P, Schneider SA Neurodegeneration with brain iron accumulation. Curr Opin Neurol 2012, 25:499-506.
172. Gregory A, Hayflick SJ Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep 2011, 11:254-261.
173. Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol 2013, 11:59-79.
174. Kruer MC, Hiken M, Gregory A, et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011, 134:947-958.
175. Kruer MC, Boddaert N, Schneider SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 2012, 33:407-414.
176. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001, 28:345-349.
177. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006, 38:752-754.
178. Kurian MA, Morgan NV, MacPherson L, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008, 70:1623-1629.
179. Kruer MC, Paisán-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010, 68:611-618.
180. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184-1191.
181. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010, 25:979-984.
182. Chien HF, Bonifati V, Barbosa ER ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Mov Disord 2011, 26:1364-1365.
183. Hayflick SJ, Kruer MC, Gregory A, et al. β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013, 136:1708-1717.
184. Madsen E, Gitlin JD Copper and iron disorders of the brain. Annu Rev Neurosci 2007, 30:317-337.
185. Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
186. Keogh MJ, Jonas P, Coulthard A, Chinnery PF, Burn J Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics 2012, 13:93-96.
187. Vidal R, Miravalle L, Gao X, et al. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci 2008, 28:60-67.
188. Deng X, Vidal R, Englander EW Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett 2010, 479:44-48.
189. Ohta E, Takiyama Y MRI findings in neuroferritinopathy. Neurol Res Int 2012, 2012:197438.
190. McNeill A, Gorman G, Khan A, Horvath R, Blamire AM, Chinnery PF Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate. AJNR Am J Neuroradiol 2012, 33:1810-1813.
191. Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord 2008, 23:751-755.
192. Walker FO Huntington's disease. Lancet 2007, 369:218-228.
193. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000, 9:2789-2797.
194. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007, 32:1655-1664.
195. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999, 56:569-574.
196. Jurgens CK, Jasinschi R, Ekin A, et al. MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr 2010, 8:RRN1173.
197. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265.
198. Allen RP, Earley CJ The role of iron in restless legs syndrome. Mov Disord 2007, 22(suppl 18):S440-S448.
199. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
200. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by Neuromelanin cells in restless legs syndrome. Neurology 2004, 62:1563-1567.
201. Ondo WG Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010, 11:494-496.
202. Duyn JH The future of ultra-high field MRI and fMRI for study of the human brain. Neuroimage 2012, 62:1241-1248.
203. Langkammer C, Schweser F, Krebs N, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012, 62:1593-1599.
204. Duyn J MR susceptibility imaging. J Magn Reson 2013, 229:198-207.
205. Fukunaga M, Li TQ, van Gelderen P, et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci USA 2010, 107:3834-3839.
206. Bian W, Harter K, Hammond-Rosenbluth KE, et al. A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler 2013, 19:69-75.
207. Kwan JY, Jeong SY, Van Gelderen P, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One 2012, 7:e35241.
208. Yablonskiy DA, Luo J, Sukstanskii AL, Iyer A, Cross AH Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis. Proc Natl Acad Sci USA 2012, 109:14212-14217.
209. Sati P, van Gelderen P, Silva AC, et al. Micro-compartment specific T2* relaxation in the brain. Neuroimage 2013, 77:268-278.
210. Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
211. Hocq A, Brouette N, Saussez S, Luhmer M, Gillis P, Gossuin Y Variable-field relaxometry of iron-containing human tissues: a preliminary study. Contrast Media Mol Imaging 2009, 4:157-164.
212. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
213. Kwiatkowski A, Ryckewaert G, Jissendi Tchofo P, et al. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 2012, 18:110-112.
214. Devos D, Moreau C, Kluza V, et al. Disease modifying strategy based upon iron chelation in Parkinson's disease: a translational study. Neurology 2012, 78(suppl):P02.240.
215. Moreau C, Devedjian J-C, Kluza J, et al. Targeting brain chelatable iron as a therapeutic strategy for Parkinson's disease. Translational and clinical studies. Am J Hematol 2013, 88:e36. (abstr).
216. Dexter D, Ward R, Crichton R, Kallo V, Srai SK Altered brain iron homeostasis in Parkinson's disease and potential for iron chelation therapy. Am J Hematol 2013, 88:e163. (abstr).
217. Crapper McLachlan DR, Kruck TP, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
218. Crouch PJ, Savva MS, Hung LW, et al. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011, 119:220-230.
219. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008, 7:779-786. on behalf of the PBT2-201-EURO study group.
220. Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
221. Loréal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002, 36:851-856.
222. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997, 41:404-407.
223. Suzuki Y, Yoshida K, Aburakawa Y, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern Med 2013, 52:1527-1530.
224. Mariani R, Arosio C, Pelucchi S, et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 2004, 53:756-758.